While Exagen Inc has overperformed by 2.13%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, XGN rose by 110.49%, with highs and lows ranging from $8.80 to $1.78, whereas the simple moving average jumped by 78.91% in the last 200 days.
On July 30, 2025, KeyBanc Capital Markets Upgraded Exagen Inc (NASDAQ: XGN) to Overweight. A report published by Craig Hallum on July 23, 2025, Initiated its previous ‘Buy’ rating for XGN. Cowen Initiated an Outperform rating on October 15, 2021, and assigned a price target of $26. Canaccord Genuity initiated its ‘Buy’ rating for XGN, as published in its report on April 15, 2021. KeyBanc Capital Markets’s report from November 10, 2020 suggests a price prediction of $32 for XGN shares, giving the stock a ‘Overweight’ rating. BTIG Research also rated the stock as ‘Buy’.
Analysis of Exagen Inc (XGN)
Further, the quarter-over-quarter increase in sales is 14.19%, showing a positive trend in the upcoming months.
One of the most important indicators of Exagen Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -87.94% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 4.59, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and XGN is recording 326.61K average volume. On a monthly basis, the volatility of the stock is set at 5.03%, whereas on a weekly basis, it is put at 6.21%, with a gain of 17.90% over the past seven days. Furthermore, long-term investors anticipate a median target price of $10.83, showing growth from the present price of $8.63, which can serve as yet another indication of whether XGN is worth investing in or should be passed over.
How Do You Analyze Exagen Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 38.53%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 28.26% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
XGN shares are owned by institutional investors to the tune of 28.26% at present.
